$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000114420413014545 Filed on March 12, 2013

Income Statement

Concept	2013 Q1	2012	2011 Q4
Revenue	$3.833M	$22.08M	$5.845M
YoY Change	-17.43%	50.3%	5745.0%
Cost Of Revenue	$1.712M	$14.69M	$3.200M
YoY Change	-54.78%	109.8%
Gross Profit	$2.121M	$7.384M	$2.600M
YoY Change	147.78%	-3.92%	2500.0%
Gross Profit Margin	55.34%	33.45%	44.48%
Selling, General & Admin	$2.900M	$10.10M	$2.500M
YoY Change	-6.45%	-7.34%	8.7%
% of Gross Profit	136.73%	136.78%	96.15%
Research & Development	$9.256M	$26.91M	$4.400M
YoY Change	73.4%	46.52%	-8.33%
% of Gross Profit	436.4%	364.4%	169.23%
Depreciation & Amortization	$400.0K	$1.700M	$400.0K
YoY Change	0.0%	6.25%	0.0%
% of Gross Profit	18.86%	23.02%	15.38%
Operating Expenses	$9.256M	$26.91M	$6.900M
YoY Change	73.4%	46.52%	-2.82%
Operating Profit	-$10.01M	-$29.67M	-$4.300M
YoY Change	33.99%	37.47%	-38.57%
Interest Expense	$22.00K	$32.00K	$500.0K
YoY Change	633.33%	255.56%	-600.0%
% of Operating Profit
Other Income/Expense, Net		$45.00K	$0.00
YoY Change		73.08%	-100.0%
Pretax Income	-$9.979M	-$28.51M	-$3.700M
YoY Change	36.03%	50.42%	-43.94%
Income Tax	$17.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.996M	-$28.51M	-$3.700M
YoY Change	36.26%	47.22%	-41.27%
Net Earnings / Revenue	-260.79%	-129.13%	-63.3%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.351M	-$4.318M	-$637.9K
COMMON SHARES
Basic Shares Outstanding	147.9M
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.30M	$44.10M	$18.30M
YoY Change	114.01%	140.98%	-42.27%
Cash & Equivalents	$9.023M	$17.40M	$14.10M
Short-Term Investments	$35.30M	$26.70M	$4.200M
Other Short-Term Assets	$886.0K	$3.800M	$1.558M
YoY Change	400.56%	-5.0%	-2.63%
Inventory
Prepaid Expenses	$2.167M		$2.441M
Receivables	$2.602M	$2.600M	$1.965M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$51.72M	$50.40M	$26.11M
YoY Change	95.61%	93.1%	-21.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.62M	$11.50M	$6.857M
YoY Change	46.14%	66.67%	-16.38%
Goodwill	$33.14M		$33.14M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$1.100M	$6.200M
YoY Change
Other Assets	$350.0K	$1.100M	$469.0K
YoY Change	0.0%	120.0%	134.5%
Total Long-Term Assets	$46.98M	$51.90M	$40.47M
YoY Change	11.34%	28.15%	-2.49%
TOTAL ASSETS
Total Short-Term Assets	$51.72M	$50.40M	$26.11M
Total Long-Term Assets	$46.98M	$51.90M	$40.47M
Total Assets	$98.70M	$102.3M	$66.58M
YoY Change	43.81%	53.6%	-10.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.173M	$3.200M	$2.645M
YoY Change	-26.56%	23.08%	-26.53%
Accrued Expenses	$5.842M	$7.300M	$4.528M
YoY Change	30.46%	62.22%	-28.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	-$20.00K
YoY Change
Long-Term Debt Due	$400.0K	$200.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$9.253M	$11.70M	$7.579M
YoY Change	18.01%	53.95%	-26.42%
LONG-TERM LIABILITIES
Long-Term Debt	$1.500M	$1.000M	$300.0K
YoY Change	275.0%	233.33%	0.0%
Other Long-Term Liabilities	$10.40M	$9.400M	$4.800M
YoY Change	70.49%	95.83%	-7.69%
Total Long-Term Liabilities	$11.90M	$10.40M	$5.100M
YoY Change	83.08%	103.92%	-7.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.253M	$11.70M	$7.579M
Total Long-Term Liabilities	$11.90M	$10.40M	$5.100M
Total Liabilities	$21.14M	$22.10M	$12.73M
YoY Change	47.67%	74.02%	-19.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$368.2M		-$329.7M
YoY Change	9.25%
Common Stock	$1.517M		$1.175M
YoY Change	23.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M		$2.450M
YoY Change	0.0%
Treasury Stock Shares	455.4K shares		$455.4K
Shareholders Equity	$77.57M	$80.20M	$53.85M
YoY Change
Total Liabilities & Shareholders Equity	$98.70M	$102.3M	$66.58M
YoY Change	43.81%	53.6%	-10.99%

Cashflow Statement

Concept	2013 Q1	2012	2011 Q4
OPERATING ACTIVITIES
Net Income	-$9.996M	-$28.51M	-$3.700M
YoY Change	36.26%	47.22%	-41.27%
Depreciation, Depletion And Amortization	$400.0K	$1.700M	$400.0K
YoY Change	0.0%	6.25%	0.0%
Cash From Operating Activities	-$10.58M	-$18.23M	-$2.800M
YoY Change	150.78%	-22.85%	-52.54%
INVESTING ACTIVITIES
Capital Expenditures	-$1.500M	-$4.340M	-$200.0K
YoY Change	87.5%	611.48%	0.0%
Acquisitions
YoY Change
Other Investing Activities	-$3.400M	-$27.92M	$1.000M
YoY Change	36.0%	-245.8%	-131.25%
Cash From Investing Activities	-$4.974M	-$32.26M	$800.0K
YoY Change	52.11%	-273.98%	-124.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$6.425M	$54.00M
YoY Change	-18.91%	391.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.181M	$53.79M	1.800M
YoY Change	-1.07%	383.3%	100.0%
NET CHANGE
Cash From Operating Activities	-$10.58M	-$18.23M	-2.800M
Cash From Investing Activities	-$4.974M	-$32.26M	800.0K
Cash From Financing Activities	$7.181M	$53.79M	1.800M
Net Change In Cash	-$8.376M	$3.295M	-200.0K
YoY Change	3525.97%	-45.47%	-97.59%
FREE CASH FLOW
Cash From Operating Activities	-$10.58M	-$18.23M	-$2.800M
Capital Expenditures	-$1.500M	-$4.340M	-$200.0K
Free Cash Flow	-$9.083M	-$13.89M	-$2.600M
YoY Change	165.58%	-39.66%	-54.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1613000	USD
CY2010	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1372000	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1666000	USD
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012Q4	nvax	Contingent Payment Amount ContingentPaymentAmount	14000000	USD
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	147944817
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012Q2	dei	Entity Public Float EntityPublicFloat	185200000	USD
CY2012	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Trading Symbol TradingSymbol	NVAX
CY2012Q4	nvax	Additional Tenant Improvement Allowance AdditionalTenantImprovementAllowance	3000000	USD
CY2012Q4	nvax	Aggregate Payments Made Per License Agreement AggregatePaymentsMadePerLicenseAgreement	5700000	USD
CY2011	nvax	Cancellation Of Previously Issued Common Stock Value CancellationOfPreviouslyIssuedCommonStockValue	50000	USD
CY2011	nvax	Capital Lease Obligation Equipment Purchased CapitalLeaseObligationEquipmentPurchased		USD
CY2010	nvax	Capital Lease Obligation Equipment Purchased CapitalLeaseObligationEquipmentPurchased		USD
CY2012	nvax	Capital Lease Obligation Equipment Purchased CapitalLeaseObligationEquipmentPurchased	399000	USD
CY2012Q3	nvax	Capital Lease Periodic Payment CapitalLeasePeriodicPayment	6325	USD
CY2012Q3	nvax	Capital Leases Of Lessee Effective Interest Rate CapitalLeasesOfLesseeEffectiveInterestRate	0.065
CY2008Q3	nvax	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.5
CY2012Q4	nvax	Common Stock Value Authorized CommonStockValueAuthorized	50000000	USD
CY2010Q1	nvax	Common Stock Value Authorized Prior Agreement CommonStockValueAuthorizedPriorAgreement	50000000	USD
CY2012Q3	nvax	Debt Instrument Term DebtInstrumentTerm	P42M
CY2011Q4	nvax	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	126020000	USD
CY2012Q4	nvax	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	135415000	USD
CY2012	nvax	Defined Contribution Plan Percent Of Employee Deferral Eligible For Employer Matching DefinedContributionPlanPercentOfEmployeeDeferralEligibleForEmployerMatching	0.06
CY2011	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment		USD
CY2010	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment		USD
CY2012	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment	500000	USD
CY2011	nvax	Fair Value Assumptions Transaction Probability Maximum FairValueAssumptionsTransactionProbabilityMaximum	0.05
CY2012	nvax	Fair Value Assumptions Transaction Probability Maximum FairValueAssumptionsTransactionProbabilityMaximum	0.05
CY2011	nvax	Fair Value Assumptions Transaction Probability Minimum FairValueAssumptionsTransactionProbabilityMinimum	0
CY2012	nvax	Fair Value Assumptions Transaction Probability Minimum FairValueAssumptionsTransactionProbabilityMinimum	0
CY2012Q4	nvax	Joint Venture Percentage Owned By Others JointVenturePercentageOwnedByOthers	0.2
CY2012Q2	nvax	Leased Facility Square Footage LeasedFacilitySquareFootage	21000
CY2012Q3	nvax	Lease Term LeaseTerm	P59M
CY2012Q4	nvax	Loan Agreement Future Minimum Payments Due LoanAgreementFutureMinimumPaymentsDue	910000	USD
CY2012Q4	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Four LoanAgreementFutureMinimumPaymentsDueInRollingYearFour	39000	USD
CY2012Q4	nvax	Leased Facility Square Footage LeasedFacilitySquareFootage	53000
CY2012Q1	nvax	Leased Facility Square Footage LeasedFacilitySquareFootage	74000
CY2012Q4	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Three LoanAgreementFutureMinimumPaymentsDueInRollingYearThree	157000	USD
CY2012Q4	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Two LoanAgreementFutureMinimumPaymentsDueInRollingYearTwo	357000	USD
CY2012Q4	nvax	Loan Agreement Future Minimum Payments Next Rolling Twelve Months LoanAgreementFutureMinimumPaymentsNextRollingTwelveMonths	357000	USD
CY2011	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	847000	USD
CY2010	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled		USD
CY2012	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled		USD
CY2012Q4	nvax	Purchase Commitment Aggregate Amount Incurred Towards Total Commitment PurchaseCommitmentAggregateAmountIncurredTowardsTotalCommitment	600000	USD
CY2012Q4	nvax	Purchase Obligation Minimum Payment Threshold PurchaseObligationMinimumPaymentThreshold	2000000	USD
CY2012Q4	nvax	Purchase Obligation Percent Of Shortfall PurchaseObligationPercentOfShortfall	0.5
CY2012Q4	nvax	Purchase Obligation Remaining Obligation PurchaseObligationRemainingObligation	6900000	USD
CY2011Q4	nvax	Research And Development Accruals ResearchAndDevelopmentAccruals	1213000	USD
CY2012Q4	nvax	Research And Development Accruals ResearchAndDevelopmentAccruals	3396000	USD
CY2011	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration		USD
CY2010	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration		USD
CY2012	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	1405000	USD
CY2011	nvax	Settlement Of Notes Receivable SettlementOfNotesReceivable	1522000	USD
CY2010	nvax	Settlement Of Notes Receivable SettlementOfNotesReceivable		USD
CY2012	nvax	Settlement Of Notes Receivable SettlementOfNotesReceivable		USD
CY2010	nvax	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.2107
CY2012Q4	nvax	Tenant Improvement Allowance TenantImprovementAllowance	2500000	USD
CY2011Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4528000	USD
CY2012Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7275000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2645000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3228000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1965000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1011000	USD
CY2011	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	317000	USD
CY2010	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	247000	USD
CY2012	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	18000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4528000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7275000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5547000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7154000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	832000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	430000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	383948000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	438939000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2047000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1339000	USD
CY2011Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	3373000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	32515000	USD
CY2011Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	4205000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	26712000	USD
CY2011Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	4205000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	32945000	USD
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	832000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	430000	USD
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1		USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1		USD
CY2011Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent		USD
CY2012Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	6233000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2091000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	246000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	468000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	365000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	100000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2047000	USD
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1339000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2091000	USD
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11284054000
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9344635000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12732383000
CY2011	us-gaap	Asset Impairment Charges AssetImpairmentCharges	360000	USD
CY2010	us-gaap	Asset Impairment Charges AssetImpairmentCharges	162000	USD
CY2012	us-gaap	Asset Impairment Charges AssetImpairmentCharges		USD
CY2011Q4	us-gaap	Assets Assets	66576000	USD
CY2012Q4	us-gaap	Assets Assets	102345000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	26109000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	50408000	USD
CY2011	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14000	USD
CY2010	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	418000	USD
CY2012	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1321000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3295000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	58000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	237000	USD
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	341000	USD
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Five CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive	44000	USD
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Four CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour	76000	USD
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Three CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree	76000	USD
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Two CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo	76000	USD
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	46000	USD
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	295000	USD
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	69000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14104000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8061000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38757000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17399000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6043000	USD
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-30696000	USD
CY2008Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	3.62
CY2008Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3343325
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117480867
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148398747
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117025437
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	147943317
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	1175000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1484000	USD
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19304000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35756000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28909000	USD
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: bold italic 10pt Times New Roman, Times, Serif"> Concentration of Credit Risk</p> <p style="FONT: italic 10pt Times New Roman, Times, Serif; FONT-STYLE: normal; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in">  </p> <p style="FONT: italic 10pt Times New Roman, Times, Serif; FONT-STYLE: normal; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"> Financial instruments, which possibly expose the Company to concentration of credit risk, consist primarily of cash and cash equivalents and investments. The Company's investment policy limits investments to certain types of instruments, including auction rate securities, high-grade corporate debt securities and money market instruments, places restrictions on maturities and concentrations in certain industries and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions, which may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents. The carrying value of cash and cash equivalents approximates their fair value based on their short-term maturities at December 31, 2012 and 2011. As discussed below, the fair value of investments is based upon Level 2 data.</p> <!--EndFragment--></div> </div>
CY2011	us-gaap	Contract Revenue Cost ContractRevenueCost	7003000	USD
CY2010	us-gaap	Contract Revenue Cost ContractRevenueCost		USD
CY2012	us-gaap	Contract Revenue Cost ContractRevenueCost	14692000	USD
CY2011	us-gaap	Contracts Revenue ContractsRevenue	14688000	USD
CY2010	us-gaap	Contracts Revenue ContractsRevenue	343000	USD
CY2012	us-gaap	Contracts Revenue ContractsRevenue	20671000	USD
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	36267000	USD
CY2010	us-gaap	Costs And Expenses CostsAndExpenses	38837000	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	51741000	USD
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		USD
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		USD
CY2011	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	412000	USD
CY2010	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		USD
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		USD
CY2012Q3	us-gaap	Debt Instrument Basis Spread On Variable Rate DebtInstrumentBasisSpreadOnVariableRate	0.1168
CY2011Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	320000	USD
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	910000	USD
CY2012Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5904000	USD
CY2012Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Minimum DebtInstrumentInterestRateStatedPercentageRateRangeMinimum	0.121
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		USD
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-450000	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		USD
CY2011Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	350000	USD
CY2012Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	335000	USD
CY2011Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	386000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	432000	USD
CY2011Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1980000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6940000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	258000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	126370000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	135750000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		USD
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	116492000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	122731000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	302394000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3974000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7326000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax	94000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	6238000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5693000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	126020000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	135415000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	350000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	335000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	88000	USD
CY2010	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	71000	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	127000	USD
CY2011	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.25
CY2012	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.5
CY2012	us-gaap	Defined Contribution Plan Maximum Annual Contribution Per Employee Percent DefinedContributionPlanMaximumAnnualContributionPerEmployeePercent	1
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1700000	USD
CY2011Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		USD
CY2012Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	267000	USD
CY2011Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	368000	USD
CY2012Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1600000	USD
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1400000	USD
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2010	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2011Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.02
CY2010	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.43
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.36
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.33
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.03
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.03
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.1
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.04
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.06
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.09
CY2012Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	3.62
CY2011	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2010	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.04
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.08
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.05
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.02
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2283000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3242000	USD
CY2008Q3	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	2.68
CY2011Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	3.62
CY2012	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2011	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y6M29D
CY2012	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P6M29D
CY2011	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.725
CY2012	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.726
CY2011	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.002
CY2012	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0011
CY2011	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2474000	USD
CY2010	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1671000	USD
CY2012	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	101000	USD
CY2011	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2010	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-35000	USD
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	28000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11379000	USD
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10805000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10988000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2011Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1836000	USD
CY2012Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1570000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18952000	USD
CY2011	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-36158000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-28507000	USD
CY2010Q4	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	100000	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	412000	USD
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	450000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2011	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	412000	USD
CY2010	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	-450000	USD
CY2012	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations		USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2686000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1912000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2009000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1911000	USD
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-204000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-954000	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2500000	USD
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-150000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	258000	USD
CY2010	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
CY2012	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	4346000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1854000	USD
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	312000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-40000	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
CY2010	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	986000	USD
CY2011	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1836000	USD
CY2010	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables		USD
CY2012	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-266000	USD
CY2011	us-gaap	Interest Expense InterestExpense	9000	USD
CY2010	us-gaap	Interest Expense InterestExpense	9000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102345000	USD
CY2011	us-gaap	Investment Income Net InvestmentIncomeNet	136000	USD
CY2010	us-gaap	Investment Income Net InvestmentIncomeNet	189000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	45000	USD
CY2012	us-gaap	Interest Expense InterestExpense	32000	USD
CY2011	us-gaap	Interest Paid InterestPaid		USD
CY2010	us-gaap	Interest Paid InterestPaid		USD
CY2012	us-gaap	Interest Paid InterestPaid	20000	USD
CY2011Q4	us-gaap	Interest Payable Current InterestPayableCurrent	32000	USD
CY2012	us-gaap	Investment Income Net InvestmentIncomeNet	165000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	12727000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	22105000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66576000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7579000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11675000	USD
CY2012	us-gaap	License Costs LicenseCosts	200000	USD
CY2011Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	300000	USD
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	753000	USD
CY2011	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		USD
CY2010	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		USD
CY2012	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	879000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-21579000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11129000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23429000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53786000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18543000	USD
CY2012Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8035000	USD
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 1 - Organization</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Novavax, Inc. (the "Company") is a clinical-stage biopharmaceutical company focused on developing recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ("VLPs") and recombinant protein micelle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target seasonal influenza, pandemic (H5N1) influenza and respiratory syncytial virus ("RSV").</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In 2009, the Company formed a joint venture with Cadila Pharmaceuticals Limited ("Cadila") named CPL Biologicals Private Limited (the "JV") to develop and manufacture vaccines, biological therapeutics and diagnostics in India. The JV is owned 20% by the Company and 80% by Cadila (See Note 7). The Company accounts for its investment in the JV using the equity method.</p> <!--EndFragment--></div> </div>
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21273000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32262000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23629000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32852000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18229000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-19364000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-35708000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-28507000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19364000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35708000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28507000	USD
CY2011Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7453000	USD
CY2011Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4993000	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3212000	USD
CY2011Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3705000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7336000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5920000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7217000	USD
CY2011Q4	us-gaap	Notes Payable Current NotesPayableCurrent	20000	USD
CY2012Q4	us-gaap	Notes Payable Current NotesPayableCurrent	157000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12404000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-38494000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-29665000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	31133000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2136000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2442000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4271000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4171000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3596000	USD
CY2012	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	4300000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	14517000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1600000	USD
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1600000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3200000	USD
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1000000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	592000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1558000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	171000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	469000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	351000	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	60000	USD
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-48000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-402000	USD
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	341000	USD
CY2010	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	282000	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-660000	USD
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26000	USD
CY2010	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	485000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	45000	USD
CY2011Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	825000	USD
CY2012Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	967000	USD
CY2011	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	200000	USD
CY2010	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	500000	USD
CY2012	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	2082000	USD
CY2010	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	38717000	USD
CY2012	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	48652000	USD
CY2011	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	610000	USD
CY2010	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1556000	USD
CY2012	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4341000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54002000	USD
CY2011	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11800000	USD
CY2010	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	23100000	USD
CY2012	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	14000000	USD
CY2008Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	17500000	USD
CY2012Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	27000000	USD
CY2012Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	12200000	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2441000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2559000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10980000	USD
CY2010	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23089000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	49900000	USD
CY2011	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
CY2010	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	650000	USD
CY2011	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-80000	USD
CY2010	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-86000	USD
CY2012	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-60000	USD
CY2011	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities		USD
CY2010	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities		USD
CY2012	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-756000	USD
CY2011	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	21235000	USD
CY2010	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	19000000	USD
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.97
CY2011	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2010	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	426000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	54000	USD
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	324000	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	179000	USD
CY2010	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	20407000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18610000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6857000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11456000	USD
CY2012Q4	us-gaap	Purchase Obligation PurchaseObligation	7500000	USD
CY2011	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	50000	USD
CY2010	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties		USD
CY2012	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties		USD
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations		USD
CY2010	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations		USD
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	104000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17885000	USD
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28032000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26061000	USD
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue		USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	986000	USD
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent		USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	756000	USD
CY2010	us-gaap	Restricted Stock Award Forfeitures RestrictedStockAwardForfeitures		USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-329656000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358163000	USD
CY2010	us-gaap	Revenue From Grants RevenueFromGrants	800000	USD
CY2011	us-gaap	Revenues Revenues	14688000	USD
CY2010	us-gaap	Revenues Revenues	343000	USD
CY2012	us-gaap	Revenues Revenues	22076000	USD
CY2011Q1	us-gaap	Revenues Revenues	834000	USD
CY2011Q2	us-gaap	Revenues Revenues	3001000	USD
CY2011Q3	us-gaap	Revenues Revenues	5008000	USD
CY2011Q4	us-gaap	Revenues Revenues	5845000	USD
CY2012Q1	us-gaap	Revenues Revenues	4642000	USD
CY2012Q2	us-gaap	Revenues Revenues	7103000	USD
CY2012Q3	us-gaap	Revenues Revenues	5765000	USD
CY2012Q4	us-gaap	Revenues Revenues	4567000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	2047000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	1339000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	2091000	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	53333
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	33334
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.63
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	19999
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.03
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.81
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.755
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0191
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.08
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.786
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0289
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.733
CY2012Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000000
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	24957715
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53155000	USD
CY2011	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0154
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0048
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0093
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0055
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	700000	USD
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	USD
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.47
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.71
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2600000	USD
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M
CY2011Q4	us-gaap	Share Price SharePrice	1.26
CY2012Q4	us-gaap	Share Price SharePrice	1.89
CY2012Q4	us-gaap	Share Price SharePrice	2.18
CY2012Q2	us-gaap	Share Price SharePrice	1.22
CY2011Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	-20000	USD
CY2012Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	-157000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	53849000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	59050000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	69952000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	80240000	USD
CY2011	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6001841
CY2010	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10513849
CY2012	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8442025
CY2008Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6686650
CY2012Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	12385321
CY2010	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	179000	USD
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	426000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions		USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions		USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions		USD
CY2011Q4	us-gaap	Supplies Supplies	1616000	USD
CY2012Q4	us-gaap	Supplies Supplies	1592000	USD
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4875000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4910000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4801000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	35000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	74000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions		USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities		USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities		USD
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: bold italic 10pt Times New Roman, Times, Serif"> Use of Estimates</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of the financial statements in conformity with accounting principles generally accepted in the United States. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</p> <!--EndFragment--></div> </div>
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	113610
CY2010	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	104768
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	131726

Files In Submission

Name	View Source	Status
0001144204-13-014545-index-headers.html	Edgar Link	pending
0001144204-13-014545-index.html	Edgar Link	pending
0001144204-13-014545.txt	Edgar Link	pending
0001144204-13-014545-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nvax-20121231.xml	Edgar Link	completed
nvax-20121231.xsd	Edgar Link	pending
nvax-20121231_cal.xml	Edgar Link	unprocessable
nvax-20121231_def.xml	Edgar Link	unprocessable
nvax-20121231_lab.xml	Edgar Link	unprocessable
nvax-20121231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlogo.jpg	Edgar Link	pending
tpg36.jpg	Edgar Link	pending
v335539_10k.htm	Edgar Link	pending
v335539_ex10-2.htm	Edgar Link	pending
v335539_ex10-32.htm	Edgar Link	pending
v335539_ex23-1.htm	Edgar Link	pending
v335539_ex3-2.htm	Edgar Link	pending
v335539_ex31-1.htm	Edgar Link	pending
v335539_ex31-2.htm	Edgar Link	pending
v335539_ex32-1.htm	Edgar Link	pending
v335539_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2013 Q1 Form 10-K Financial Statement

#000114420413014545 Filed on March 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2013 Q1 Form 10-K Financial Statement

#000114420413014545 Filed on March 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax